Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

GRF

Eagle Capital Growth (GRF)

Eagle Capital Growth Fund Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:GRF
DateTimeSourceHeadlineSymbolCompany
14/01/202522:00GlobeNewswire Inc.Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s DiseaseAMEX:GRFEagle Capital Growth Fund Inc
27/12/202405:40Edgar (US Regulatory)Form 40-17G - Fidelity Bond [Rule 17G-1(g)]AMEX:GRFEagle Capital Growth Fund Inc
06/12/202407:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
20/11/202400:00GlobeNewswire Inc.GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B VirusAMEX:GRFEagle Capital Growth Fund Inc
19/11/202408:00Business WireEagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in CashAMEX:GRFEagle Capital Growth Fund Inc
29/10/202423:00GlobeNewswire Inc.Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant SolutionAMEX:GRFEagle Capital Growth Fund Inc
22/10/202423:00GlobeNewswire Inc.Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye InjuryAMEX:GRFEagle Capital Growth Fund Inc
04/10/202400:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
03/10/202422:00GlobeNewswire Inc.GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional BiothreatAMEX:GRFEagle Capital Growth Fund Inc
11/09/202403:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
11/09/202403:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
30/08/202404:08Edgar (US Regulatory)Form N-PX - Annual Report of proxy voting record of management investment companiesAMEX:GRFEagle Capital Growth Fund Inc
21/08/202404:02Edgar (US Regulatory)Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)AMEX:GRFEagle Capital Growth Fund Inc
31/07/202422:00GlobeNewswire Inc.GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339AMEX:GRFEagle Capital Growth Fund Inc
29/07/202422:00GlobeNewswire Inc.Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patientsAMEX:GRFEagle Capital Growth Fund Inc
01/07/202420:00GlobeNewswire Inc.Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven yearsAMEX:GRFEagle Capital Growth Fund Inc
18/06/202421:30GlobeNewswire Inc.Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier GroupAMEX:GRFEagle Capital Growth Fund Inc
17/06/202418:20GlobeNewswire Inc.Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficienciesAMEX:GRFEagle Capital Growth Fund Inc
25/05/202405:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
18/04/202423:30GlobeNewswire Inc.Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.AMEX:GRFEagle Capital Growth Fund Inc
04/04/202419:00GlobeNewswire Inc.Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus ScreeningAMEX:GRFEagle Capital Growth Fund Inc
08/03/202403:11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:GRFEagle Capital Growth Fund Inc
07/03/202404:56Edgar (US Regulatory)Form N-CSR - Certified Shareholder ReportAMEX:GRFEagle Capital Growth Fund Inc
29/02/202403:20Edgar (US Regulatory)Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)AMEX:GRFEagle Capital Growth Fund Inc
24/02/202408:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
24/02/202408:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
14/02/202419:16GlobeNewswire Inc.Grifols announces positive topline phase 3 fibrinogen clinical trial resultsAMEX:GRFEagle Capital Growth Fund Inc
14/02/202407:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
14/02/202407:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
14/02/202407:09Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesAMEX:GRFEagle Capital Growth Fund Inc
 Showing the most relevant articles for your search:AMEX:GRF

Your Recent History

Delayed Upgrade Clock